NeuExcell Therapeutics Hits New Milestone in Treatment of Malignant Glioma with NXL-004
NeuExcell Therapeutics has successfully given the dosing of the first patient with the first-in-class NeuroD1 gene therapy product NXL-004.
Clinical Study | 22/03/2024 | By Manvi | 185
Anti-Tigit drug of Roche fails stage study
Roche's Genentech had disappointing news to share this week regarding its lung cancer hopeful.
Clinical Study | 26/04/2022 | By Sudeep Soparkar | 589
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy